Charles River Laboratories International Inc. (CRL) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Charles River Laboratories International Inc. (NYSE: CRL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $359.41 (-4.44% 1D, market cap $17.95B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, CRL ranks #144 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), CRL carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 0.4%. By comparison, MEDP (Medpace Holdings Inc.) holds a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B) and ICLR (ICON plc) posts a B- grade (71/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.50B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
Per CRL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001100682), Charles River Laboratories International Inc. generated $4.02B in revenue (-0.9% YoY), -$144.3M in net income, and $557.0M in free cash flow against $7.14B in total assets and $1.77B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8.3% realized swing band)
SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($557.0M FCF) & 52% Gross Margin
Cannibal Buyback (-0.68% YoY Shares) & executive Form 4 sales trim 10 pts from alignment
Even with a 63/100 (C) score, CRL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($305.08) or 200D SMA ($223.33) invalidates the momentum regime and cuts Target Base ($367.50) toward Bear Floor ($286.65).
Charles River Laboratories International Inc. (CRL) dropped -4.44% to $359.41, trading at 91% of its 52-week range ($146.2 – $379.63). Solid steady margins (0% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash f
Charles River Laboratories International (NYSE:CRL) agreed to deploy its Virtual Control Group database for Ipsen to support toxicology studies and reduce animal use. The Ipsen collaboration uses AI powered analytics and
Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cerv
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Charles River Laboratories International Inc. (CRL) ranks #144 by composite RQD confidence (63/100, grade C) and #75 by equity capitalization ($17.95B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with CRL at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRL
ACTIVE
Charles River Laboratories International Inc. | C | 63/100 | — | — | 0.4% | -4.44% | $17.95B | Benchmark Subject |
| MEDP Medpace Holdings Inc. | B+ | 80/100 | 42.0x | — | 27.9% | -3.77% | $18.95B | /medp-vs-crl → |
| ICLR ICON plc | B- | 71/100 | 71.9x | — | 3.1% | -1.91% | $16.50B | /iclr-vs-crl → |
| INCY Incyte Corp. | A- | 84/100 | 18.4x | 92.8% | 42.4% | +3.07% | $23.68B | /incy-vs-crl → |
| IQV IQVIA Holdings Inc. | C | 64/100 | 33.3x | — | 9.4% | -2.81% | $45.33B | /iqv-vs-crl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-27), Charles River Laboratories International Inc. (CRL) reported GAAP revenue of $4.02B (-0.9% vs. FY2024 revenue of $4.05B , and -2.8% cumulative change since FY2023) , GAAP net income of -$144.3M, operating cash flow of $737.6M, and free cash flow of $557.0M (+0.8% YoY). On the balance sheet, CRL closed FY2025 with $7.14B in total assets against $1.77B in total debt (Altman Z-Score: 3.65, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-27 | $4.02B | -$144.3M | $737.6M | $557.0M | $7.14B | $1.77B |
| FY2024 (FY) | 2024-12-28 | $4.05B | $22.2M | $734.6M | $552.3M | $7.53B | $1.81B |
| FY2023 (FY) | 2023-12-30 | $4.13B | $474.6M | $683.9M | $498.1M | $9.88B | $2.31B |
As of 2026-11-02, Charles River Laboratories International Inc. (NYSE: CRL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $359.41 (-4.44% 1D, market cap $17.95B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 10/20. Across 1016 tracked Health Care issuers, CRL ranks #144 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), CRL carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 0.4%. By comparison, MEDP (Medpace Holdings Inc.) holds a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B) and ICLR (ICON plc) posts a B- grade (71/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.50B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
Per CRL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-27, CIK 0001100682), Charles River Laboratories International Inc. generated $4.02B in revenue (-0.9% YoY), -$144.3M in net income, and $557.0M in free cash flow against $7.14B in total assets and $1.77B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CRL last traded at $359.41 (-4.44% on volume of 1,503,897 shares), positioning the stock +17.81% above its 50-day simple moving average ($305.08) and +60.93% above its 200-day simple moving average ($223.33). Across its 52-week range of $146.20 to $379.63, CRL sits at the 91.3% percentile with a 14-day RSI of 72.7 (OVERBOUGHT (>70)) and an implied next-earnings move of ±8.3% ($329.58 to $389.24).
Why CRL Stock dropped -4.44% Today — RQD Quant Desk Flash. Solid steady margins (0% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Per the Roarable RQD rating, CRL scores 63 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 13/20 (ROIC 0.4%; FCF yield 3.1%), Whale 13F Flow at 18/20 (institutional accumulation and options positioning), Insider Conviction at 10/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.15; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 3.65; Piotroski F 6/9; Debt/Equity 0.52).
The strongest pillar is institutional flow, which is the main upside driver in this rating. The weakest pillars are insider conviction and macro regime fit, which indicate limited insider-level confirmation and above-market sensitivity to broad moves (Beta 1.15). The fundamental pillar is modest, reflecting a 0.4% ROIC against a 3.1% FCF yield, so valuation support rests more on cash generation than on returns on invested capital. A prospective investor should weigh the strong flow signal against a valuation that the source data shows at a forward P/E of 23 and an EV/EBITDA of 95, a combination that leaves limited margin for error if cash generation or sentiment weakens.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $4015.4M | $25.2M | $-144.3M | N/A | $557.0M | $213.8M | $1765.9M |
| FY 2024 | $4050.0M | $227.3M | $22.2M | N/A | $552.3M | $194.6M | $1809.1M |
| FY 2023 | $4129.4M | $617.3M | $474.6M | N/A | $498.1M | N/A | $2310.8M |
Per the SEC financials, revenue was broadly flat across the three reported years while operating income declined from $617.3M in FY 2023 to $25.2M in FY 2025, and FY 2025 net income was negative at $-144.3M. Market data shows an operating margin of 0.6% and a net margin of -3.6%, with ROIC at 0.4%. Per the Roarable RQD rating, the Altman Z-Score is 3.65 and the Piotroski F-Score is 6/9, and Debt/Equity is 0.52. Free cash flow remained positive at $557.0M in FY 2025, and reported debt declined from $2310.8M in FY 2023 to $1765.9M in FY 2025.
The news feed contains six items, all tagged to CRL, and none includes substantive narrative beyond headlines and summaries. Items are labeled as market wire, catalyst, or market-wire items by impact classification. The headlines reference a strong trading day and outperformance versus competitors, a 12-month price target raised to $324.87 implying 8% upside, a GuruFocus GF Score of 64/100 with an overvalued GF Value designation, and a Simply Wall St piece on holder returns. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded, so no proprietary signal analysis is available. Risk watch items based on the feed are the conflict between the raised price target and the GuruFocus overvaluation label, and the gap between the 52-week high of $379.63 and the current price of $376.1.
Real-time company headlines, analyst actions, and sector developments for Charles River Laboratories International Inc. (CRL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
MarketWatch report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Charles River Laboratories International Inc. (CRL) market action, institutional positioning, and fundamental catalysts.
CRL's Q3'26 results face pressure from declining segment revenues, but improving biopharma demand and strength in Microbial Solutions could provide support.
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash f
Welcome to the CRL (Charles River Laboratories International Inc.) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CRL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Charles River Laboratories International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CRL, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $376.10 (52-wk range $146.20 - $379.63), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).